EU/3/19/2190

About

On 21 August 2019, orphan designation EU/3/19/2190 was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for peginterferon lambda-1a for the treatment of hepatitis D virus infection.

The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in October 2019.

Key facts

Active substance
Peginterferon lambda-1a
Disease / condition
Treatment of hepatitis D virus infection
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2190

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Eigerbio Europe Limited
1 Castlewood Avenue
Rathmines
Dublin 6
D06 H685
Ireland
E-mail: info@eigerbio.com 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating